Predominance of MGMT promoter methylation among Pakistani glioblastoma patients-Reference-Cited by-同舟云学术

Predominance of MGMT promoter methylation among Pakistani glioblastoma patients

Published:2024-03-23 Issue:1 Volume:51 Page:
ISSN:0301-4851
Container-title:Molecular Biology Reports
language:en
Short-container-title:Mol Biol Rep

Author:

Muhammad Noor,Fasih Samir,Malik Bilal,Hameed Shahid,Loya Asif,Rashid Muhammad Usman^ORCID

Funder

Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11033-024-09363-2.pdf

Reference39 articles.

1. Global Cancer Statistics (2020) : https://gco.iarc.fr/today/data/factsheets/populations/586-pakistan-fact-sheets.pdf. Date accessed: September 10, 2023

2. Badar F, Mahmood S, Yusuf MA, Sultan F (2016) Epidemiology of cancers in Lahore, Pakistan, 2010–2012: a cross-sectional study. BMJ Open 6:e011828. https://doi.org/10.1136/bmjopen-2016-011828

3. Maile EJ, Barnes I, Finlayson AE, Sayeed S, Ali R (2016) Nervous system and intracranial tumour incidence by ethnicity in England, 2001–2007: a descriptive epidemiological study. PLoS ONE 11:e0154347. https://doi.org/10.1371/journal.pone.0154347

4. Ahsan J, Hashmi SN, Muhammad I, Din HU, Butt AM, Nazir S, Azhar M (2015) Spectrum of central nervous system tumours–a single center histopathological review of 761 cases over 5 years. J Ayub Med Coll Abbottabad 27:81–84

5. Crinière E, Kaloshi G, Laigle-Donadey F, Lejeune J, Auger N, Benouaich-Amiel A, Everhard S, Mokhtari K, Polivka M, Delattre J-Y (2007) MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol 83:173–179. https://doi.org/10.1007/s11060-006-9320-0